mycophenolic acid

Summary

Summary: An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)

Top Publications

  1. ncbi Review of major clinical trials with mycophenolate mofetil in renal transplantation
    Gaetano Ciancio
    Department of Surgery, Division of Transplantation, Lillian Jean Kaplan Renal Transplant Center, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33101, USA
    Transplantation 80:S191-200. 2005
  2. ncbi Reduced exposure to calcineurin inhibitors in renal transplantation
    Henrik Ekberg
    Lund University, Malmo, Sweden
    N Engl J Med 357:2562-75. 2007
  3. pmc Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
    Gerald B Appel
    Department of Nephrology, Columbia University, New York, New York, USA
    J Am Soc Nephrol 20:1103-12. 2009
  4. ncbi Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
    Klemens Budde
    Department of Nephrology, Charite University, Berlin, Germany
    Lancet 377:837-47. 2011
  5. ncbi Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
    Hepatology 55:1673-83. 2012
  6. ncbi Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
  7. pmc Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
    Frédéric A Houssiau
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Saint Luc University Hospital, Brussels 1200, Belgium
    Ann Rheum Dis 69:2083-9. 2010
  8. ncbi Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells
    Michele Andreucci
    Chair of Nephrology, Magna Graecia University, Catanzaro, Italy
    Chem Biol Interact 185:253-62. 2010
  9. ncbi The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro
    Karin Hoppe-Seyler
    Molecular Therapy of Virus Associated Cancers, German Cancer Research Center DKFZ, Heidelberg, Germany
    Hepatology 56:9-16. 2012
  10. ncbi Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?
    W Arns
    Cologne General Hospital, Merheim Medical Center, Cologne, Germany
    Transplant Proc 39:88-93. 2007

Research Grants

Detail Information

Publications356 found, 100 shown here

  1. ncbi Review of major clinical trials with mycophenolate mofetil in renal transplantation
    Gaetano Ciancio
    Department of Surgery, Division of Transplantation, Lillian Jean Kaplan Renal Transplant Center, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33101, USA
    Transplantation 80:S191-200. 2005
    ....
  2. ncbi Reduced exposure to calcineurin inhibitors in renal transplantation
    Henrik Ekberg
    Lund University, Malmo, Sweden
    N Engl J Med 357:2562-75. 2007
    ..Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens...
  3. pmc Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
    Gerald B Appel
    Department of Nephrology, Columbia University, New York, New York, USA
    J Am Soc Nephrol 20:1103-12. 2009
    ..Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis...
  4. ncbi Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
    Klemens Budde
    Department of Nephrology, Charite University, Berlin, Germany
    Lancet 377:837-47. 2011
    ..Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy...
  5. ncbi Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
    Hepatology 55:1673-83. 2012
    b>Mycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity against different viruses and can act in synergy with interferon-α (IFN-α) on hepatitis C virus (HCV) replication...
  6. ncbi Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  7. pmc Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
    Frédéric A Houssiau
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Saint Luc University Hospital, Brussels 1200, Belgium
    Ann Rheum Dis 69:2083-9. 2010
    ..This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment...
  8. ncbi Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells
    Michele Andreucci
    Chair of Nephrology, Magna Graecia University, Catanzaro, Italy
    Chem Biol Interact 185:253-62. 2010
    ..Interleukin (IL)-8 production also increased upon H(2)O(2) stimulation. Pre-incubation of the cells with mycophenolic acid (MPA) resulted in reduced phosphorylation of both JNKs and NF-kappaB, and reduced IL-8 release in H(2)O(2)-..
  9. ncbi The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro
    Karin Hoppe-Seyler
    Molecular Therapy of Virus Associated Cancers, German Cancer Research Center DKFZ, Heidelberg, Germany
    Hepatology 56:9-16. 2012
    ..This activity is shared by mycophenolic acid (MPA), an inhibitor of purine biosynthesis...
  10. ncbi Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?
    W Arns
    Cologne General Hospital, Merheim Medical Center, Cologne, Germany
    Transplant Proc 39:88-93. 2007
    b>Mycophenolic acid (MPA), a reversible inhibitor of inosine 5''-monophosphate dehydrogenase (IMPDH), selectively inhibits T- and B-cell proliferation. MPA exposure correlates inversely with the risk of acute rejection...
  11. pmc Versatile enzyme expression and characterization system for Aspergillus nidulans, with the Penicillium brevicompactum polyketide synthase gene from the mycophenolic acid gene cluster as a test case
    Bjarne G Hansen
    Technical University of Denmark, Department of Systems Biology, Center for Microbial Biotechnology, Building 223, 2800 Kgs Lyngby, Denmark
    Appl Environ Microbiol 77:3044-51. 2011
    ..expressing mpaC or mutated mpaC genes unequivocally demonstrated that mpaC indeed encodes a polyketide synthase that produces the first intermediate in the production of the medically important immunosuppressant mycophenolic acid.
  12. ncbi Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA
    Michael S Diamond
    Division of Infectious Diseases, School of Public Health, University of California, Berkeley 94720 7360, USA
    Virology 304:211-21. 2002
    ..We assessed the ability of mycophenolic acid (MPA), a drug currently used as an immunosuppressive agent, to inhibit dengue virus (DV) antigen expression, ..
  13. ncbi Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
    Christine E Staatz
    School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
    Clin Pharmacokinet 46:13-58. 2007
    ..b>Mycophenolic acid (MPA) is the active drug moiety...
  14. ncbi Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype
    D N Eissens
    Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Am J Transplant 10:1981-90. 2010
    Cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic acid (MPA) are frequently used for GVHD prophylaxis and treatment after allogeneic stem cell transplantation (SCT)...
  15. ncbi Calcineurin inhibitor-free protocols: risks and benefits
    A G Barbari
    Saudi J Kidney Dis Transpl 18:1-23. 2007
    ....
  16. ncbi Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial
    Markus Guba
    Department of Surgery, Munich University Hospital, Campus Grosshadern, Munich, Germany
    Transplantation 90:175-83. 2010
    ..De novo sirolimus in calcineurin inhibitor-free regimens, although potentially useful to improve early renal function, are complicated by various drug-related side effects...
  17. ncbi Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism
    L Hedstrom
    Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco 94143
    Biochemistry 29:849-54. 1990
    ..b>Mycophenolic acid is also an uncompetitive inhibitor versus IMP and noncompetitive versus NAD...
  18. ncbi Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
    Dirk R J Kuypers
    Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
    Clin J Am Soc Nephrol 5:341-58. 2010
    With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need for more accurate drug dosing has become evident...
  19. ncbi Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study
    Y Lebranchu
    Service Nephrologie Immunologie Clinique, CHRU Tours, EA 4245, University Francois Rabelais, Tours, France
    Am J Transplant 9:1115-23. 2009
    ..Significantly, more patients in the SRL group reported aphthous, diarrhea, acne and high triglyceride levels. Conversion CsA to SRL 3 months after transplantation combined with MMF is associated with improvement in renal function...
  20. ncbi One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients
    H T Silva
    Hospital do Rim E Hipertansã, Sao Paulo, Brazil
    Am J Transplant 7:595-608. 2007
    ..The results support the safety and efficacy of tacrolimus in combination with MMF, corticosteroids and basiliximab induction, as well as XL as a safe and effective once-daily dosing alternative...
  21. ncbi Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
    Jai Radhakrishnan
    Department of Medicine, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA
    Kidney Int 77:152-60. 2010
    ..Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC...
  22. pmc Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
    Federico Mingozzi
    Division of Hematology and Center for Cellular and Molecular Therapeutics, The Children s Hospital of Philadelphia, PA 19104, USA
    Blood 110:2334-41. 2007
    ....
  23. ncbi Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin
    Martin J Hoogduijn
    Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
    Transplantation 86:1283-91. 2008
    ..The molecular targets of these drugs are expressed in MSC, but the effect of their inhibition on MSC functioning is unknown...
  24. pmc Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy
    Haiyan Jiang
    Bayer HealthCare Pharmaceuticals, 800 Dwight Way, Berkeley, CA 94710, USA
    Blood 108:3321-8. 2006
    ..These findings enable a clinical study to assess the effects of immunomodulation on long-term FIX expression in patients with hemophilia B...
  25. ncbi Malignancy after transplantation
    Joseph F Buell
    Israel Penn International Transplant Tumor Registry, University of Cincinnati, Cincinnati, OH 45267 0558, USA
    Transplantation 80:S254-64. 2005
    ..Long-term data are needed to determine if the use of these agents will ultimately lower the mortality due to malignancy for transplant recipients...
  26. ncbi Updates on the treatment of lupus nephritis
    Andrew S Bomback
    Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Am Soc Nephrol 21:2028-35. 2010
    ..Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials...
  27. pmc Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid
    G A Köhler
    Department of Stomatology, University of California San Francisco, 94143 0422, USA
    J Bacteriol 179:2331-8. 1997
    ..Growth of wild-type (sensitive) C. albicans cells is inhibited at 1 microg of mycophenolic acid (MPA), a specific inhibitor of IMP dehydrogenases, per ml, whereas transformants hosting a plasmid with the ..
  28. ncbi Inhibition of dengue virus replication by mycophenolic acid and ribavirin
    Ratree Takhampunya
    Department of Microbiology and Immunology, Georgetown University School of Medicine, 3900 Reservoir Road, Washington, DC 20057, USA
    J Gen Virol 87:1947-52. 2006
    ..The effects of mycophenolic acid (MPA) and ribavirin (RBV) on DEN replication in monkey kidney (LLC-MK2) cells were examined. MPA (IC(50)=0...
  29. ncbi Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
    Wolfgang Arns
    Merheim Medical Center, Cologne General Hospital, Cologne, Germany
    Clin Transplant 19:199-206. 2005
    b>Mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF), is routinely used as an adjunct immunosuppressant therapy in renal transplantation...
  30. ncbi Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha
    Scot D Henry
    Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Gastroenterology 131:1452-62. 2006
    ..Cyclosporine A (CsA) specifically inhibits HCV replication through blocking the viral RNA polymerase enzyme NS5B. In this study, we investigated the effect of mycophenolic acid (MPA) and other immunosuppressants on HCV replication.
  31. ncbi Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study
    Klemens Budde
    University Hospital Charite, Berlin, Germany
    Am J Transplant 4:237-43. 2004
    ..8%; MMF 4.9%; p=NS) were observed in both groups. In conclusion, renal maintenance patients can be converted from MMF to EC-MPS without compromising the safety and efficacy profile associated with MMF...
  32. ncbi New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation
    Hylke de Jonge
    Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
    Ther Drug Monit 31:416-35. 2009
    ..these new insights for the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus and the antimetabolite mycophenolic acid (MPA) and will discuss the possible consequences...
  33. ncbi Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin
    Sebastiaan Heidt
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Transplantation 86:1292-300. 2008
    ..In general, humoral rejection is treated with standard immunosuppressive drugs. The direct effect of these immunosuppressive drugs on B cells is not well known...
  34. ncbi Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature
    Wolfgang Arns
    Transplant Department, Merheim Medical Center, Cologne General Hospital, Cologne, Germany
    Transplantation 82:1004-12. 2006
    ..MMF) has conventionally been administered at a fixed dose without routinely monitoring blood levels of mycophenolic acid (MPA), the active metabolite...
  35. ncbi Effects of mycophenolic acid on endothelial cells
    Yanfei Huang
    Research Institute of Nephrology, Jingling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China
    Int Immunopharmacol 5:1029-39. 2005
    ..In the present study, the effect of mycophenolic acid (MPA), the active metabolite of MMF, on human umbilical vein endothelial cells (HUVECs) was investigated...
  36. ncbi Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation
    H Ekberg
    Lund University, Malmo, Sweden
    Am J Transplant 9:1876-85. 2009
    ....
  37. ncbi Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production
    Sibylle von Vietinghoff
    Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Kidney Int 78:79-88. 2010
    b>Mycophenolic acid is a commonly used immunosuppressant after organ transplantation and in autoimmune diseases; however, myelosuppression is a major complication despite its largely favorable side-effect profile...
  38. pmc Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells
    Jorg Fellenberg
    Department of Experimental Orthopedics, Orthopedic University Hospital Heidelberg, Heidelberg, Germany
    PLoS ONE 5:e12179. 2010
    ..The aim of this study was to provide evidence for direct involvement of IMPDH2 in the development of chemoresistance...
  39. pmc Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts
    Dj Miljkovic
    Institute for Biological Research Sinisa Stankovic, School of Medicine, University of Belgrade, Belgrade, Yugoslavia
    Clin Exp Immunol 132:239-46. 2003
    ..We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis ..
  40. ncbi Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?
    Sander I van Leuven
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Cardiovasc Res 69:341-7. 2006
    ..The present review provides an overview of the potential anti-atherogenic properties of MMF...
  41. ncbi Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo
    C Morath
    Department of Nephrology, University of Heidelberg, Germany
    Am J Transplant 8:1786-97. 2008
    b>Mycophenolic acid (MPA) is a potent inhibitor of the inosine monophosphate dehydrogenase and used as an immunosuppressive drug in transplantation. MPA inhibits proliferation of T- and B-lymphocytes by guanosine depletion...
  42. doi Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant
    Gerhard Opelz
    Transplantation 86:371-6. 2008
    ..Data are scarce concerning the impact of maintenance immunosuppression dose reductions posttransplant...
  43. ncbi Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
    Matthew R Weir
    Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Kidney Int 79:897-907. 2011
    ..Thus, compared with MMF/CNI treatment, a 2-year regimen of MMF/SRL resulted in similar measures of renal function but with fewer deaths and a trend to less BPAR and graft loss...
  44. ncbi Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis
    G Li
    Medical Service, Middleton Veterans Administration Hospital, Madison, Wisconsin 53705, USA
    Endocrinology 139:3752-62. 1998
    Inhibitors of IMP dehydrogenase, such as mycophenolic acid (MPA) and mizoribine, which deplete cellular GTP, are used clinically as immunosuppressive drugs...
  45. ncbi A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation
    Flora Tshinanu Musuamba
    Louvain Drug Research Institute, Louvain Centre for Toxicology and applied Pharmacology, LDRI PKDM B1 73 13, Av E Mounier 73, 1200 Bruxelles, Belgique
    J Clin Pharmacol 52:1833-43. 2012
    b>Mycophenolic acid (MPA) and tacrolimus (TAC) are immunosuppressive agents used in combination with corticosteroids for the prevention of acute rejection after solid organ transplantation...
  46. pmc Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells
    Li Ye
    Center for Animal Experiment, ABSL 3 Laboratory, Wuhan University, Hubei 430071, China
    Virus Res 168:33-40. 2012
    ..It is of interest to further determine whether MMF is indeed beneficial for HCV-infected transplant recipients in future clinical studies...
  47. ncbi Simultaneous determination of ochratoxin A, mycophenolic acid and fumonisin B(2) in meat products
    Louise Marie Sørensen
    Department of Systems Biology, Technical University of Denmark, Building 221, 2800, Lyngby, Denmark
    Anal Bioanal Chem 398:1535-42. 2010
    Here we present a method for simultaneous determination of the fungal metabolites mycophenolic acid, ochratoxin A (OTA) and fumonisin B(2) (FB(2)) in meat products...
  48. ncbi Determination of mycophenolic acid in human plasma by high-performance liquid chromatography
    V Srivatsan
    Bioanalytical Department, Lambda Therapeutic Research Pvt Ltd, 42 Premier House 1, Gandhinagar Sarkhej Highway, Bodakdev, Ahmedabad 380 054, India
    J Chromatogr A 1031:259-64. 2004
    ..validation and evaluation of high-performance liquid chromatography (HPLC) method for quantifying mycophenolic acid in human plasma is described...
  49. pmc Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice
    Sander I van Leuven
    Department of Medicine Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Ann Rheum Dis 71:408-14. 2012
    ..The current study aims to determine the benefit of lymphocyte inhibition on reducing the atherosclerotic burden in SLE-susceptible LDLr-deficient mice...
  50. ncbi Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors
    Paula S Montenegro-Miranda
    Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, 1105 BK Amsterdam, The Netherlands
    Hum Gene Ther 22:605-12. 2011
    ..In fact, clinical relevant concentrations of mycophenolic acid (MPA), the active compound of MMF, also impair the transduction of HEK-293T cells by ssAAV...
  51. ncbi The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United kingdom
    Sapna Shah
    Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Transplantation 86:1035-42. 2008
    ..The consequences, however, of dose reduction of mycophenolate mofetil relative to azathioprine have not been reported...
  52. pmc Impact of mycophenolic acid on the functionality of human polymorphonuclear neutrophils and dendritic cells during interaction with Aspergillus fumigatus
    Markus Mezger
    Medizinische Klinik II, Universitat Wurzburg, 97070 Wurzburg, Germany
    Antimicrob Agents Chemother 52:2644-6. 2008
    b>Mycophenolic acid (MPA) is used clinically to prevent graft rejection but may increase the risk of fungal infection...
  53. pmc Randomized trial of immunosuppressive regimens in renal transplantation
    Giselle Guerra
    Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, P O Box 012440 R 440, Miami, FL 33101, USA
    J Am Soc Nephrol 22:1758-68. 2011
    ..Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus...
  54. pmc Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity
    M L Ritter
    Department of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA
    Transpl Infect Dis 11:290-7. 2009
    ..A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients...
  55. ncbi Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients
    P Massari
    Servicio de Nefrologia, Hospital Privado Centro Médico, Cordoba, Argentina
    Transplant Proc 37:916-9. 2005
    ..The requirement for EC-MPS dose reduction to manage AEs was relatively low. Use of EC-MPS is a valid alternative for renal transplant recipients receiving maintenance MMF treatment...
  56. ncbi Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients
    Howard J Eisen
    Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102 1192, USA
    J Heart Lung Transplant 24:517-25. 2005
    ..This study reports the 36-month results of a randomized, double-blind, active-controlled trial of mycophenolate mofetil (MMF) vs azathioprine (AZA) in heart transplant patients...
  57. ncbi Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies
    Suphamai Bunnapradist
    David Geffen School of Medicine, Department of Medicine, Division of Nephrology, Los Angeles, CA 90095 7306, USA
    Clin Transplant 22:815-21. 2008
    ..In conclusion, monitoring of GI complications is essential following renal transplantation, and maintaining adequate mycophenolic acid exposure should be a priority when considering treatment options.
  58. ncbi Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients
    Gerardo Machnicki
    Novartis Pharmaceuticals, East Hanover, New Jersey, USA
    Pharmacoeconomics 26:951-67. 2008
    ..This analysis was undertaken to assess the 3-year economic and clinical impact of mycophenolate mofetil dosage modifications or discontinuation following post-transplant GI events compared with no dosage modification...
  59. ncbi Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians
    Claudio Ponticelli
    Nephrology and Dialysis Unit, Scientific Institute Humanitas, Rozzano, Milano, Italy
    Transpl Int 23:1126-34. 2010
    ..816; P<0.0001). Gastrointestinal symptoms are frequent in renal transplant patients, are under-evaluated by physicians and may adversely impact on patient QOL...
  60. ncbi Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients
    H Tedesco Silva
    Hospital do Rim e Hipertensao, Sao Paulo, Brazil
    Am J Transplant 10:1401-13. 2010
    ..5 or 3.0 mg/day (target troughs 3-8 and 6-12 ng/mL, respectively) with reduced-exposure CsA, or mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA. Patients received basiliximab +/- corticosteroids...
  61. ncbi Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients
    Matthew Cooper
    Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Transplantation 88:514-20. 2009
    ....
  62. ncbi Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide
    Murray B Urowitz
    University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:1491-6. 2007
    ..To assess outcomes in patients with lupus nephritis treated with immunosuppressives compared to those treated with cyclophosphamide in a cohort study and in a matched cohort study...
  63. ncbi Illumina-microarray analysis of mycophenolic acid-induced cell death in an insulin-producing cell line and primary rat islet cells: new insights into apoptotic pathways involved
    Yun Jong Park
    The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea
    Cell Signal 22:1773-82. 2010
    b>Mycophenolic acid (MPA), widely used to prevent organ transplant rejection, may induce toxicity and impair function in beta-cells. Mechanisms of MPA-induced cell death have not been fully explored...
  64. ncbi Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal
    Neal M Davies
    Nephrol Dial Transplant 22:2440-8. 2007
    ..The effects of MMF and EC-MPS are likely mediated via the active metabolite mycophenolic acid (MPA)...
  65. ncbi Dissection of the molecular basis of mycophenolate resistance in Saccharomyces cerevisiae
    M Harley Jenks
    Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
    Yeast 22:1181-90. 2005
    ..Although Imd2 is 92% identical to Imd3, it is the only S. cerevisiae IMPDH that is resistant to mycophenolic acid in vitro and is the only one of the four that supports drug-resistant growth. Thus, S...
  66. ncbi Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response
    Rolf Weimer
    Department of Internal Medicine, University of Giessen, Klinikstrasse 36, Giessen, Germany
    Transpl Int 24:596-609. 2011
    ....
  67. ncbi Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients
    Dirk R J Kuypers
    Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
    Clin Ther 30:673-83. 2008
    ..In both studies, target mycophenolic acid (MPA) AUC(0-12 h) ranges (ie, values used to guide MMF dosing) were derived from a previous study ..
  68. ncbi Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review
    Simon R Knight
    Transplantation 85:1675-85. 2008
    ..A number of factors interact to result in variability in blood levels of mycophenolic acid (MPA) increasing the risk of toxicity...
  69. ncbi Methanol-associated matrix effects in electrospray ionization tandem mass spectrometry
    Thomas M Annesley
    Department of Pathology, University of Michigan Health Sciences Center, Ann Arbor, MI, USA
    Clin Chem 53:1827-34. 2007
    ..Preliminary observations indicated that the methanol used in the mobile phase could be a source of differential ionization or ion suppression...
  70. pmc Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes
    Peter A Gottlieb
    Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver, Aurora, Colorado, USA
    Diabetes Care 33:826-32. 2010
    ..This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes...
  71. pmc Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum
    Torsten Bak Regueira
    Department of Systems Biology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
    Appl Environ Microbiol 77:3035-43. 2011
    b>Mycophenolic acid (MPA) is the active ingredient in the increasingly important immunosuppressive pharmaceuticals CellCept (Roche) and Myfortic (Novartis)...
  72. ncbi The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line
    Yun Jong Park
    The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, South Korea
    Cell Signal 21:356-64. 2009
    b>Mycophenolic acid (MPA)-induced beta-cell toxicity is an important factor for islet graft function. The signal transduction mechanisms underlying this process have not been fully explored...
  73. ncbi Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy
    Rupinderjeet Kaur
    Department of Medicine, Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    AIDS Res Hum Retroviruses 21:116-24. 2005
    Mycophenolate mofetil (MMF), the bioavailable form of mycophenolic acid (MPA), has been proposed as adjuvant therapy for human immunodeficiency virus type 1 (HIV-1) infection...
  74. ncbi Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation
    Gerhard Opelz
    Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 87:795-802. 2009
    ..There have been striking changes during the last 10 years concerning the choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney transplantation...
  75. ncbi Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression
    Thomas Satterwhite
    Department of Pediatrics, Stanford University School of Medicine, 269 Campus Drive, CCSR, Stanford, California 94305, USA
    Pediatr Transplant 7:53-8. 2003
    ....
  76. ncbi Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
    Sander I van Leuven
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Atherosclerosis 211:231-6. 2010
    ..These changes include reduced inflammatory cell presence with a concomitant decrease in pro-inflammatory gene expression...
  77. ncbi Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid
    Susan Yung
    University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Arthritis Rheum 60:2071-82. 2009
    ..The effects of mycophenolic acid (MPA) on this pathway, and the effects of mycophenolate mofetil (MMF) treatment in (NZB x NZW)F(1)/J mice ..
  78. ncbi Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
    G Contreras
    Division of Nephrology, Miller School of Medicine, University of Miami, Florida 33136, USA
    Lupus 14:s33-8. 2005
    ..Maintenance therapies with MMF or AZA following short-term CY induction in a sequential regimen are efficacious and safe for the treatment of high-risk patients with proliferative lupus nephritis...
  79. ncbi Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids
    M Buchler
    Francois Rabelais University, Department of Nephrology and Clinical Immunology, Bretonneau Hospital, CHU Tours, France
    Am J Transplant 7:2522-31. 2007
    ..23%, p < 0.01). A CNI-free regimen using sirolimus-MMF can achieve excellent renal function, but patients on sirolimus experienced a high rate of adverse events and study drug discontinuation...
  80. pmc Saccharomyces cerevisiae transcription elongation mutants are defective in PUR5 induction in response to nucleotide depletion
    R J Shaw
    Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Mol Cell Biol 20:7427-37. 2000
    ..An optimally functioning elongation machinery is critical for this response...
  81. pmc Mycophenolate mofetil for ocular inflammation
    Ebenezer Daniel
    The Fundus Photograph Reading Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Ophthalmol 149:423-32.e1-2. 2010
    ..To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases...
  82. ncbi The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
    Dirk R J Kuypers
    Department of Nephrology and Renal Transplantation, Laboratory of Absorption and Digestion, University Hospitals Leuven, Belgium
    Clin Pharmacol Ther 78:351-61. 2005
    b>Mycophenolic acid (MPA), an effective immunosuppressive drug used in renal transplantation, is extensively glucuronidated by several uridine diphosphate-glucuronosyltransferases (UGTs) into an inactive 7-O-glucuronide and, to a lesser ..
  83. pmc The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase
    Maria Pia Dell'Oglio
    Renal, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
    J Am Soc Nephrol 21:2157-68. 2010
    b>Mycophenolic acid (MPA) appears to have anti-fibrotic effects, but the molecular mechanisms underlying this are unknown. We prospectively studied 35 stable kidney transplant recipients maintained on cyclosporine and azathioprine...
  84. ncbi Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report
    J A Kobashigawa
    University of California at Los Angeles, Los Angeles, CA
    Am J Transplant 6:1377-86. 2006
    ....
  85. pmc Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway
    Arjang Djamali
    Department of Medicine, University of Wisconsin Madison SMPH, Madison, WI, USA
    Transplantation 90:387-93. 2010
    ..We evaluated the role of renal tubular Nox-2 in the pathogenesis of epithelial-to-mesenchymal transition (EMT) in kidney allografts...
  86. ncbi Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil
    M Mourad
    Department of Kidney and Pancreas Transplantation, University Hospital Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate, 10, 1200 Brussels, Belgium
    Clin Chem 47:88-94. 2001
    ..This study was designed to investigate the relationship between the clinical events and the pharmacokinetics of mycophenolic acid (MPA) in adult renal transplantation.
  87. ncbi A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
    B Bolwell
    Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 34:621-5. 2004
    ....
  88. ncbi Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cells
    Won Seok Yang
    Division of Nephrology, Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea
    Atherosclerosis 211:48-54. 2010
    ..This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-..
  89. ncbi Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs
    Mauro J C Salles
    Clinical of Infectious Diseases, Department of Internal Medicine, Santa Casa of Sao Paulo School of Medicine, Sao Paulo, Brazil
    Clin Transplant 24:E17-23. 2010
    ..This study prospectively accessed the immune response to the inactivated influenza vaccine in renal transplant recipients receiving either azathioprine or mycophenolate mofetil (MMF). Side effects were investigated...
  90. ncbi Mycophenolic acid antagonizes the activation of cultured human mesangial cells
    Isabelle Dubus
    Unité INSERM 441 Avenue du Haut Lévêque, 33600 Pessac, France
    Kidney Int 62:857-67. 2002
    ..Mycophenolate mofetil (MMF), the precursor of mycophenolic acid (MPA), is currently used in organ transplantation and has been shown to be protective in clinical and ..
  91. ncbi Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
    Stefan Vitko
    Institute of Clinical and Experimental Medicine, Praha, Czech Republic
    Am J Transplant 5:2521-30. 2005
    ..Renal dysfunction in everolimus cohorts necessitates close monitoring...
  92. ncbi Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats
    Abdul R Asif
    Abteilung Klinische Chemie, Georg August Universitat, Robert Koch Strasse 40, D 37075 Gottingen, Germany
    Biochimie 89:393-402. 2007
    Covalent binding of the acyl glucuronide (AcMPAG) metabolite of the immunosuppressant mycophenolic acid (MPA) to proteins is considered a possible initiating event for organ toxicity...
  93. ncbi Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation
    John F Valente
    Department of Surgery, Division of Nephrology, University Hospitals of Cleveland, Cleveland, OH, USA
    Am J Transplant 3:1128-34. 2003
    ....
  94. ncbi In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil
    Nina Roos
    Institut National de la Santé et de la Recherche Médicale U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Pharmacol Exp Ther 321:583-9. 2007
    ..g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD...
  95. ncbi Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis
    Lucia Sobrin
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts 02142, USA
    Ophthalmology 115:1416-21, 1421.e1. 2008
    ..To evaluate the outcomes of treatment with mycophenolate mofetil in patients with scleritis and uveitis refractory to or intolerant of methotrexate...
  96. ncbi Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial
    C Grootscholten
    Division of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Kidney Int 70:732-42. 2006
    ..At last follow-up, there were no differences in serum creatinine or proteinuria between the two groups. However, since our study lacked sufficient power, longer follow-up is needed to reveal putative differences...
  97. ncbi The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures
    Faramarz Dehghani
    Institute of Anatomy, Hospital of the Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Federal Republic of Germany
    Eur J Neurosci 18:1061-72. 2003
    ..In conclusion, MMF inhibits proliferation and activation of microglia and astrocytes and protects neurons after excitotoxic injury...
  98. ncbi Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial
    R S Gaston
    University of Alabama at Birmingham, Birmingham, AL, USA
    Am J Transplant 9:1607-19. 2009
    ..More recent data indicate a relationship between mycophenolic acid (MPA) exposure in individuals and clinical endpoints of rejection and toxicity...
  99. ncbi Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium
    Bruce Kaplan
    Division of Nephrology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610 0224, USA
    Clin Transplant 19:551-8. 2005
    Enteric-coated mycophenolate sodium (EC-MPS) (myfortic) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small ..
  100. ncbi Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis
    Jason Moore
    Department of Nephrology and Kidney Transplantation, Renal Institute of Birmingham, University Hospital Birmingham, Edgbaston, Birmingham, United Kingdom
    Transplantation 87:591-605. 2009
    ..In an attempt to aid clarification, we conducted a systematic review and meta-analysis of randomized trials that assessed CNI sparing (minimization or elimination) with mycophenolate as sole adjunctive immunosuppression...
  101. ncbi Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation
    Magdi Shehata
    Transplant Unit, Nottingham University Hospital, City Hospital Campus, Hucknall Road, Nottingham, UK
    Transpl Int 22:821-30. 2009
    ..randomized trial has evaluated whether conversion from mycophenolate mofetil (MMF) to EC-MPS permits mycophenolic acid dose to be increased or gastrointestinal side-effects to be ameliorated...

Research Grants62

  1. Herb-Drug Glucuronidation Interactions
    Reginald F Frye; Fiscal Year: 2011
    ..project are to determine in healthy volunteers: 1) the effect of prolonged Ginkgo biloba administration on mycophenolic acid pharmacokinetics;and 2) the effect of green tea leaf extract administration on raloxifene pharmacokinetics...
  2. T and B cell Homeostasis After Induction Therapy in Kidney Transplantation
    Fadi G Lakkis; Fiscal Year: 2013
    ..induction to Thymoglobulin induction in patients receiving identical maintenance immunosuppression (mycophenolic acid + Tacrolimus + early corticosteroid withdrawal)...
  3. ANTITUMOR DRUG EFFECTS ON PHOSPHATIDYLINOSITIDE TURNOVER
    JOHANNA STOECKLER; Fiscal Year: 1990
    ..Antimetabolites that deplete cellular GTP, i.e., selenazofurin and mycophenolic acid, or that form GTP analogs, i.e...
  4. Nanotherapeutics for combined immunesuppression in organ transplantation
    DANIEL ROBERT GOLDSTEIN; Fiscal Year: 2013
    ..We hypothesize that co-encapsulation of the commonly employed immune suppressive medications rapamycin and mycophenolic acid into FDA- approved poly(lactic-co-glycolic acid) (PLGA) nanoparticles will prolong allograft survival and ..
  5. PURINE METABOLISM IN TRICHOMONAS AND GIARDIA
    C Wang; Fiscal Year: 2000
    ..for comparison, our biochemical data on the parasite enzyme have already indicated an unusually high K1 for mycophenolic acid and identified Cys319 in the enzyme as the catalytic nucleophile...
  6. NOVEL COFACTOR ANALOGUES AS IMMUNOSUPPRESSANTS
    Krzysztof Pankiewicz; Fiscal Year: 2000
    ..affinity towards IMPDH has been achieved by replacement of the nicotinamide riboside portion of NAD with mycophenolic acid (MPA) derivatives...
  7. Novel agents against West Nile Virus infections
    Krzysztof Pankiewicz; Fiscal Year: 2003
    ..Among them, mycophenolic acid (MPA) was one of the most potent compounds...
  8. IMP DEHYDROGENASE FROM PNEUMOCYSTIS AS A DRUG TARGET
    SHERRY QUEENER; Fiscal Year: 2000
    ..Two known inhibitors of IMPDH (mycophenolic acid and tiazofurin) are strong inhibitors of P...
  9. DESIGN, SYNTHESIS AND STUDY OF IMPD INHIBITORS
    Wayne Anderson; Fiscal Year: 1993
    ..b>Mycophenolic acid (MPA), a mould metabolite, is one of the most potent IMPD inhibitors known, however the phenolic hydroxyl in ..
  10. NOVEL BENZAMIDE RIBOSIDE ANALOGUES AS ANTICANCER AGENTS
    Krzysztof Pankiewicz; Fiscal Year: 2001
    ..PROPOSED COMMERCIAL APPLICATION: Ribavirin (antiviral) and mycophenolic acid (immunosuppressant) are clinically used drugs that express their activity through inhibition of inosine ..
  11. Purine salvage in Cryptosporidium parvum
    Mitchell Abrahamsen; Fiscal Year: 2005
    ..parvum inosine monophosphate dehydrogenase (cplMPDH) was identified as a suppressor of mycophenolic acid sensitivity in a Toxoplasma gondii strain defective for HXGPRT, a key gene in the purine salvage pathway of ..
  12. NOVEL DIFFERENTIATION AGENTS AGAINST HUMAN LEUKEMIAS
    Krzysztof Pankiewicz; Fiscal Year: 2000
    ..PROPOSED COMMERCIAL APPLICATIONS: Ribavirin (antiviral) and mycophenolic acid (immunosuppressant) are clinically useful drugs expressing their activity due to inhibition of inosine ..
  13. BOTANICAL/DRUG INTERACTIONS IN HIV: GLUCURONIDATION
    Philip Smith; Fiscal Year: 2004
    ..conjugative metabolic pathway important for the elimination of azidothymidine, abacavir, efavirenz,and mycophenolic acid. Glucuronidation is the major Phase II metabolic pathway, but is much less studied that oxidative metabolism...
  14. ACTIVATION OF CHEMOTHERAPEUTIC AGENTS IN LEUKEMIC CELLS
    Donna Shewach; Fiscal Year: 1992
    ..corresponding deoxyribonucleoside, or depleted by incubating the cells with phosphonoacetyl-L-aspartate and mycophenolic acid, which are inhibitors of pyrimidine and purine biosynthesis, respectively...
  15. ARBOVIRUS REPLICATION IN MOSQUITO AND VERTEBRATE CELLS
    Victor Stollar; Fiscal Year: 1991
    ..and have low levels of ado met, 2) SVmpa, which can grow in mosquito cells which have been treated with mycophenolic acid, and have low levels of GTP, 3) Svcp which shows increased cytopathogenicity for mosquito cells, 4) SVcl35 ..
  16. ROLE OF INTESTINAL UGT IN DRUG DISPOSITION
    Philip Smith; Fiscal Year: 2005
    ..b>Mycophenolic acid (MPA, immunosuppressant) and SN-38 (antitumor), are active compounds derived from prodrugs MMF and ..
  17. HTLV Receptor Identification and Characterization
    Lee Ratner; Fiscal Year: 2005
    ..vector expressing drug resistance markers, and selection carried out sequentially with G418, puromycin, and mycophenolic acid. Selected cells will be screened with an HTLV envelope pseudotyped HIV vector expressing luciferase, and the ..
  18. VIRUSES, ACQUIRED IMMUNODEFICIENCY, AND KAPOSI'S SARCOMA
    Martin Hirsch; Fiscal Year: 1993
    ..Rescue analysis will be assessed by use of selective markers (resistance to mycophenolic acid), polymerase chain reaction assays of secondarily infected fibroblasts, and detection of HIV-1 antigen ..
  19. Novel inhibitors of the replication of poxviruses
    Johan Neyts; Fiscal Year: 2004
    ..The final goal of this application is to advance a compound for the treatment of (systemic or cutaneous) poxvirus infections to the initial stages of development, i.e., selecting an IND candidate. ..
  20. Recurrence of T1D in Pancreas Transplantation
    George Burke; Fiscal Year: 2009
    ..The knowledge gained should also be relevant to islet cell transplantation and spontaneous disease. ..
  21. Pharmacokinetics & Genomics in Glomerular Diseases
    MELANIE JOY; Fiscal Year: 2008
    ..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..
  22. African American Study of Kidney Disease and Hypertensi*
    Gabriel Contreras; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  23. Visual outcomes & quality of life in CMV retinitis
    Jennifer Thorne; Fiscal Year: 2006
    ..abstract_text> ..
  24. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  25. Clinical Translational Research in Transplant Nephrology
    Bryan Becker; Fiscal Year: 2006
    ..It will also work to meet the NIH's goal of increasing the number of physician-scientists conducting high-quality patient-oriented research. ..
  26. Function & Fate of Alloantigen-specific CD8 Cell in GVHD
    Paul Martin; Fiscal Year: 2005
    ..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
  27. Regulation of GnRH Neuronal Development by FGF Signaling
    John Gill; Fiscal Year: 2005
    ..Critical stages of GnRH neuron development will be evaluated in mice to discern the functional contribution of FGF signaling in this important neuroendocrine system. ..
  28. RENAL MEDULLARY NITRIC OXIDE AND BLOOD PRESSURE
    David Mattson; Fiscal Year: 2001
    ....
  29. E M Transdifferentiation in Proximal Tubule Cells
    Bryan Becker; Fiscal Year: 2004
    ..abstract_text> ..
  30. Clonal Selection in Diabetic Nephropathy
    Oliver Lenz; Fiscal Year: 2003
    ..The long-term goal of our proposal is to characterize the role of clonal selection in glomerular disease, and identify new targets for screening, prevention, and intervention in the pathogenesis of diabetic nephropathy. ..
  31. TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS
    Paul Martin; Fiscal Year: 2002
    ..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..
  32. Angiotensin II Receptor Blockade and Chronic Rejection
    Bryan Becker; Fiscal Year: 2003
    ....
  33. OPTIMIZATION OF HUMAN FETAL PANCREAS FOR TRANSPLANTATION
    Hans Sollinger; Fiscal Year: 2001
    ..The results of these studies will provide a sufficient source of HFP tissue for clinical transplantation which responds to glucose challenge and requires minimal immunosuppressive therapy. ..
  34. GBV-B: A SMALL PRIMATE MODEL FOR HEPATITIS C INFECTION
    Robert Lanford; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  35. Resolution of Acute Hepatitis B Virus Infections in Chimpanzees
    Robert Lanford; Fiscal Year: 2008
    ..Our long-term objective is to apply our understanding of the resolution of acute HBV infection to the development of effective new immunotherapies for chronic HBV infections. [unreadable] [unreadable] [unreadable]..
  36. IMPDH as a Drug Target in Cryptosporidium
    Boris Striepen; Fiscal Year: 2008
    ..This work will provide urgently needed molecular reagents to understand the biology of nutrient uptake and drug resistance in this unique parasite. [unreadable] [unreadable] [unreadable]..
  37. Jo-1-specific T Cell Responses in Polymyositis
    DANA ASCHERMAN; Fiscal Year: 2007
    ..These studies are intended to also provide insight concerning the relative roles of altered T cell repertoire and antigen presentation in the expression of Jo-1+ polymyositis. ..
  38. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  39. Repression of HIV Transcription: from mechanism to anti-latency therapies
    David Margolis; Fiscal Year: 2007
    ..abstract_text> ..
  40. Pathogenesis of Otitis Media with Effusion
    Patricia A Hebda; Fiscal Year: 2010
    ..With these studies the investigators hope to elucidate the role of specific inflammatory signals and pathways in promoting disease persistence, and thus to identify potential targets for future therapeutic interventions. ..
  41. Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts
    BRENDA MARIE SANDMAIER; Fiscal Year: 2010
    ..The final, and most important, studies will involve determining the quantity of 211At-labeled MAb required to obtain stable engraftment in HCT involvingDLA- haploidentical littermates. ..
  42. Chicago Islet Consortium ICR at UIC
    Jose Oberholzer; Fiscal Year: 2008
    ..In addition, and most importantly for the progres of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients. ..
  43. Improving Platelet Recovery After Radiation
    George Georges; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  44. Regulation of Mammalian Oocyte Maturation
    Stephen Downs; Fiscal Year: 2007
    ..Furthermore, these studies will benefit the development of in vitro systems where either meiotic arrest or completion of meiotic maturation is the desired endpoint. ..
  45. BIOSYNTHESIS OF SOME MICROBIAL METABOLITES
    Ronald Parry; Fiscal Year: 2007
    ..Future investigations of sparsomycin will focus on cloning the sparsomycin resistance gene from S. sparsogenes to understand the mechanism of self-resistance in this organism and to gain access to the biosynthetic genes. ..
  46. BIOSYNTHESIS AND METABOLISM OF CYCLOPENTANOIDS
    Ronald Parry; Fiscal Year: 2001
    ..The potential use of the CmaA gene for construction of hybrid peptide antibiotics containing L-alloisoleucine or coronamic acid will also be explored, using surfactin biosynthesis in B. subtilis as a model system. ..
  47. QUALITY OF LIFE AND COST EFFECTIVENESS IN CMV RETINITIS
    John Kempen; Fiscal Year: 2002
    ..Subanalyses will assess what factors other than treatment strategy are associated with improved QOL and cost-effectiveness. ..
  48. JCV Virus Expression in Oropharynx and HIV
    Joseph Berger; Fiscal Year: 2004
    ..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
  49. Proteomic and mRNA Profiling of Urine and Urine Sediment
    Brad Rovin; Fiscal Year: 2004
    ..abstract_text> ..
  50. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  51. YEAST GENES INVOLVED IN GENERAL TRANSCRIPTIONAL CONTROL
    CLYDE DENIS; Fiscal Year: 2003
    ..The key features of the ADH2 promoter which are responsive to the CCR4-NOT complex will be identified to determine how the CCR4-NOT complex controls the ADH2 gene in a positive manner. ..
  52. Gene Expression Analyses During IFN Antiviral Therapy
    Robert Lanford; Fiscal Year: 2005
    ..These data will help determine why interferon therapy is often unsuccessful for chronic HCV infections and provide cellular targets for future therapies. ..
  53. Bone Marrow Angioblasts For Cardiac Regeneration
    Silviu Itescu; Fiscal Year: 2004
    ....
  54. A cell-free system for exocytosis in the beta-cell
    SUSANNE STRAUB SHARP; Fiscal Year: 2005
    ..physiological mechanisms such as time-dependent potentiation and biphasic insulin release. The method will also allow the study of some aspects of endocytosis. ..
  55. PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONS
    Jean Claude Bystryn; Fiscal Year: 2005
    ..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
  56. Cytokines for Immune Protection from Acute Irradiation
    George Georges; Fiscal Year: 2005
    ..The secondary endpoint is immune reconstitution. Upon study completion, we will have identified the optimal cytokine treatment and the highest dose of TBI that can be reliably survived without HSC support. ..
  57. Novel Therapies for Resistant FSGS
    Howard Trachtman; Fiscal Year: 2006
    ..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
  58. ICAM1 gene inactivation protects against ischemic injury
    Robert Montgomery; Fiscal Year: 2006
    ..This work has important implications for the selective inactivation of gene function in allografts through ex vivo gene transfer. ..
  59. Repression of HIV Transcription-A Pathway to Quiescence
    David Margolis; Fiscal Year: 2006
    ..abstract_text> ..
  60. Longitudinal Studies of Primary Biliary Cirrhosis
    MARLYN MAYO; Fiscal Year: 2006
    ..In addition, the correlation between each of the putative surrogate markers will be analyzed. The results of this analysis will then be used to design future clinical trials in the field of PBC. [unreadable] [unreadable]..
  61. Experimental Dysautonomia: Pathogenesis and Treatment
    Steven Vernino; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  62. CHEMOKINE REGULATION IN IMMUNE COMPLEX RENAL DISEASE
    Brad Rovin; Fiscal Year: 2001
    ..This information will likely suggest new directions for interventions to control renal inflammation. ..